Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
Rhea-AI Summary
Outset Medical (Nasdaq: OM) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. A conference call with CEO Leslie Trigg and CFO Renee Gaeta is scheduled the same day at 1:30 p.m. PT / 4:30 p.m. ET.
Registration is required to join the call; a live and archived webcast will be available on the company’s Investors website.
Positive
- None.
Negative
- None.
News Market Reaction – OM
In the Apr 28 session, OM declined 2.04%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Earnings date notice | Neutral | +14.3% | Set date and time for Q4 2025 results call with leadership participation. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings-date communication on Jan 26, 2026 coincided with a strong positive +14.29% move, indicating past sensitivity to scheduling earnings updates.
Over recent months, Outset Medical has combined operational and regulatory milestones with financial updates. In Jan 2026, it announced FDA clearance for the next-generation Tablo platform and scheduled its Q4/FY 2025 earnings call, which preceded a +14.29% move. Subsequent earnings detailed $119.5M 2025 revenue and a 39.1% gross margin. Management changes and inducement grants in Apr 2026 further shaped the story. Today’s announcement continues the pattern of pre-announcing earnings dates with investor calls.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced that it will release financial results for the first quarter 2026 after the close of trading on Thursday, May 7, 2026.
On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results.
Conference Call Details
The conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Thursday, May 7, 2026. Those interested in joining the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.
Contact
Jim Mazzola
jmazzola@outsetmedical.com
